Amalgamated Bank’s Summit Therapeutics SMMT Stock Holding History

Amalgamated Bank’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,465	Closed	-$166K	–	2644
2025 Q4	$166K	Buy	9,465 +913	+11%	+$17.2K	﹤0.01%	1605
2025 Q3	$177K	Buy	8,552 +609	+8%	+$14.8K	﹤0.01%	1599
2025 Q2	$169K	Buy	7,943 +4,758	+149%	+$109K	﹤0.01%	1591
2025 Q1	$61K	Buy	3,185 +156	+5%	+$3.13K	﹤0.01%	1761
2024 Q4	$54K	Hold	3,029	–	–	﹤0.01%	1821
2024 Q3	$66K	Hold	3,029	–	–	﹤0.01%	1777
2024 Q2	$24K	Sell	3,029 -878	-22%	-$4.74K	﹤0.01%	2057
2024 Q1	$16K	Sell	3,907 -12,498	-76%	-$49.7K	﹤0.01%	2238
2023 Q4	$43K	Sell	16,405 -1,163	-7%	-$2.39K	﹤0.01%	2321
2023 Q3	$33K	Hold	17,568	–	–	﹤0.01%	2431
2023 Q2	$44K	Buy	+17,568	New	+$32.1K	﹤0.01%	2378
2022 Q2	–	Sell	-4,291	Closed	-$11K	–	3182
2022 Q1	$11K	Buy	+4,291	New	+$10.8K	﹤0.01%	2945

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Amalgamated Bank's SMMT Position: Q1 2026 in Review

Amalgamated Bank sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 9,465 shares — an estimated $166K sold.

Amalgamated Bank first reported a position in SMMT in Q1 2022 and held it in 12 quarters. The position peaked at $177K in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Amalgamated Bank reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 9,465 Summit Therapeutics shares in Q1 2026, an estimated $166K.
Amalgamated Bank first reported a position in Summit Therapeutics in Q1 2022 and held it in 12 quarters.
Amalgamated Bank's Summit Therapeutics position peaked at $177K in Q3 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.